Combination pharmacotherapy for tackling descending controls and central sensitisation

Abstract

In this issue you will find a paper by Stevie Lockwood and Anthony Dickenson entitled “A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain” (Lockwood and Dickenson, 2019). This electrophysiological study in the monoiodoacetate (MIA) model of osteoarthritis in rats has important implications for personalised pain management, suggesting that patients with dysfunctional descending pain control will likely benefit from noradrenaline reuptake inhibitors (“endogenous pain control boosters”), while patients with evidence for central sensitisation are likely to benefit from gabapentinoids.

This article is protected by copyright. All rights reserved.

from Wiley: European Journal of Pain: Table of Contents https://ift.tt/2FLIjR5
via IFTTT